OptimizeRx Corporation (OPRX) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (67% profit margin, 7% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-01, OptimizeRx Corporation (NASDAQ: OPRX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $9.37 (+0.75% 1D, market cap $176.5M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 15/20. Across 1011 tracked Consumer Discretionary issuers, OPRX ranks #187 in composite RQD confidence.
Within the Consumer Discretionary sector (Business Services), OPRX carries a Roarable B- (70/100 RQD), trailing P/E of 34.4x, gross margin of 67.3%, and ROIC of 7.3%. By comparison, UXIN (Uxin Limited ADS) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M) and DHX (DHI Group Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -7.4%, cap $210.2M). Among the 5-stock peer group, OPRX leads on earnings multiple (34.4x) while OPRX leads on capital efficiency (7.3% ROIC).
Per OPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001448431), OptimizeRx Corporation generated $109.4M in revenue (+18.8% YoY), $5.1M in net income, and $18.7M in free cash flow against $176.9M in total assets and $21.4M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 29% of 52W Range • RSI-14 at 63.6 (BULLISH MOMENTUM)
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)
Even with a 70/100 (B-) score, OPRX faces multiple-compression risk if 34.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 64.8% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($8.20) or 200D SMA ($7.30) invalidates the momentum regime and cuts Target Base ($9.88) toward Bear Floor ($7.68).
OptimizeRx Corporation (OPRX) advanced +0.75% to $9.37, trading at 29% of its 52-week range ($4.54 – $21.09). High-quality cash engine (67% profit margin, 7% return on capital) with steady institutional support.
WALTHAM, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare profess
Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflowsWALTHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX),
White Brook Capital’s Q3 2026 investor letter expresses cautious optimism. Its Ethical All-Cap Strategy has outperformed, while the Small Cap Strategy has lagged because of execution delays, higher interest rates, and ma
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +18.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OPRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OPRX. Explore sector supply chains on /butterfly.
Across 1011 tracked Consumer Discretionary securities in the Roarable RQD universe, OptimizeRx Corporation (OPRX) ranks #187 by composite RQD confidence (70/100, grade B-) and #708 by equity capitalization ($176.5M). Within this direct 5-issuer industry benchmark cohort, OPRX leads on earnings valuation at 34.4x trailing P/E, while OPRX leads on capital efficiency and profitability with 7.3% ROIC and 67.3% gross margin. OPRX currently leads its immediate peer cohort in composite quantitative strength at 70/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OPRX
ACTIVE
OptimizeRx Corporation | B- | 70/100 | 34.4x | 67.3% | 7.3% | +0.75% | $176.5M | Benchmark Subject |
| UXIN Uxin Limited ADS | D- | 38/100 | — | 6.7% | -35.0% | -1.00% | $206.8M | /uxin-vs-oprx → |
| DHX DHI Group Inc. | D+ | 52/100 | — | 84.7% | -7.4% | -0.21% | $210.2M | /dhx-vs-oprx → |
| CNDT Conduent Incorporated | E | 29/100 | — | 18.1% | -24.8% | -1.90% | $241.1M | /cndt-vs-oprx → |
| ALIT Alight Inc. (Class A) | D- | 36/100 | — | 33.8% | -35.0% | +1.44% | $247.0M | /alit-vs-oprx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), OptimizeRx Corporation (OPRX) reported GAAP revenue of $109.4M (+18.8% vs. FY2024 revenue of $92.1M , and +53.0% cumulative change since FY2023) , GAAP net income of $5.1M, operating cash flow of $18.7M, and free cash flow of $18.7M (+290.6% YoY). On the balance sheet, OPRX closed FY2025 with $176.9M in total assets against $21.4M in total debt (Altman Z-Score: 2.68, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $109.4M | $5.1M | $18.7M | $18.7M | $176.9M | $21.4M |
| FY2024 (FY) | 2024-12-31 | $92.1M | -$20.1M | $4.9M | $4.8M | $171.2M | $30.8M |
| FY2023 (FY) | 2023-12-31 | $71.5M | -$17.6M | -$7.2M | -$7.2M | — | — |
As of 2026-11-01, OptimizeRx Corporation (NASDAQ: OPRX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $9.37 (+0.75% 1D, market cap $176.5M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 15/20. Across 1011 tracked Consumer Discretionary issuers, OPRX ranks #187 in composite RQD confidence.
Within the Consumer Discretionary sector (Business Services), OPRX carries a Roarable B- (70/100 RQD), trailing P/E of 34.4x, gross margin of 67.3%, and ROIC of 7.3%. By comparison, UXIN (Uxin Limited ADS) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M) and DHX (DHI Group Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -7.4%, cap $210.2M). Among the 5-stock peer group, OPRX leads on earnings multiple (34.4x) while OPRX leads on capital efficiency (7.3% ROIC).
Per OPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001448431), OptimizeRx Corporation generated $109.4M in revenue (+18.8% YoY), $5.1M in net income, and $18.7M in free cash flow against $176.9M in total assets and $21.4M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
OPRX last traded at $9.37 (+0.75% on volume of 100,522 shares), positioning the stock +14.27% above its 50-day simple moving average ($8.20) and +28.36% above its 200-day simple moving average ($7.30). Across its 52-week range of $4.54 to $21.09, OPRX sits at the 29.2% percentile with a 14-day RSI of 63.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.7% ($8.37 to $10.37).
Why OPRX Stock advanced +0.75% Today — RQD Quant Desk Flash. High-quality cash engine (67% profit margin, 7% return on capital) with steady institutional support.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.